Cylerion Therapeutics, Inc. (NASDAQ: CYCN) Reports a Net Loss of $16.2 Million in The Second Quarter of 2021

Cylerion Therapeutics, Inc. (NASDAQ: CYCN), a biopharmaceutical company whose mission is to develop treatments that restore cognitive function, recently reported financial results for 2Q2021 and provided general corporate and pipeline updates. Second-quarter summary The company’s cash and cash equivalents at the end of the second quarter were approximately $70 million, […]


Cyclerion Therapeutics (NASDAQ: CYCN) Gains 30.16% Following Deal with Akebia for Praliciguat’s Development

Cyclerion Therapeutics (NASDAQ: CYCN) stock jumped 30.16% after the company revealed a series of insider purchases. CEO Peter M Hecht, director Terrance Mcguire, and top institutional shareholder Slate Path Capital purchased 1.9 million shares of the company in separate transactions on June 3 for a combined total value of $6.0 […]